Structurally defined proteins and peptides have provided considerable information about the specificity and regulation of immune responses in inbred animals. Many diabetics require therapy with insulin; therefore, we used this defined protein as a model antigen to investigate immune responses in the outbred human population. In this report, we examine human T cell recognition of antigenic determinants on various insulins. A group of 25 subjects was selected from over 200 diabetics because of the magnitude of their in vitro responses. 13 of the 25 had significant T cell responses to human insulin despite treatment with only beef/pork insulin mixtures. This autoimmunity may be attributed to crossreactivity of lymphocytes highly reactive to "foreign" epitopes on therapeutic insulins. Alternatively, identical determinants shared by human and animal insulins may be recognized. By employing additional insulins not used therapeutically and isolated A and B chains, several potential mechanisms for lymphocyte autoreactivity to human insulin were demonstrated. Some epitopes are conformational and require recognition of an intact molecule, whereas other epitopes may arise from antigen processing at the cellular level. Studies using zinc-free insulins suggest that zinc-induced alterations of the molecular surface may result in some shared reactivities between animal and human insulin. Furthermore, T cell reactivity against "foreign" epitopes is more complex than anticipated from differences in amino acid sequence. The response patterns of many subjects indicate that the A-chain loop associates with the N-terminal B chain to form a complex determinant. This determinant is recognized more often than individual amino acids. We conclude that insulin therapy generates polyclonal T cell responses directed at multiple epitopes on the molecule. Many of these epitopes are not identified by amino acid exchanges and their presence on human insulin leads to apparent autoimmunity.
Introduction
Insulin is a two-chain globular protein, the molecular structure of which has been extensively characterized. This structure is highly conserved through evolution and the limited amino acid differences in mammalian insulins ( Fig. 1 ) occur at positions that do not alter molecular conformation or affect biologic function (1) . The naturally occurring amino acid substitutions are on the surface of the molecule where amino acids that comprise the A-chain loop (A8, A9, A10) are closely associated with the Receivedfor publication 26 February 1985 and in revisedform 24 June 1985. B-chain terminus (2, 3). Two 5, 750 ,000-mol wt insulin monomers form a dimer held together by ionic interactions and, in the presence of Zn2", dimers assemble into hexamers that interact to form larger aggregates (2, 4). These more complex molecular forms are favored by the increased concentrations of insulin found in islets and in therapeutic preparations (U-100 insulin is 4 mg/ml) where hexamers are the major molecular form (2). Recently, zinc has been shown to induce alterations in the surface ofthe insulin molecule that result in the exposure of amino acid side chains that are normally buried in monomer (4) . Diabetics treated with insulin, therefore, may be exposed to molecules with alterations owing to zinc-induced changes on the surface or to the approximation in hexamers of residues not associated in the monomer. Either of these alterations may be potential targets ofthe immune system that is tolerant to circulating insulin monomers.
The majority of insulin-treated diabetics develop antibodies after therapy with animal insulins. Immunologic complications such as allergy and resistance have been documented even with the use of highly purified and human insulin preparations (5) (6) (7) (8) . Data from inbred animals show that the immune response to epitopes on insulin is controlled at the cellular level by major histocompatibility complex-linked immune-response genes (9-1 1). A recent report of statistical associations between HLA-DR type and responses to therapeutic insulin components supports the concept that similar immune-response genes are present in the outbred human population ( 12) . In those studies, the critical epitopes on the insulin molecule recognized by T lymphocytes were surmised from amino acid differences between autologous insulin and immunizing insulins. Several recent studies, however, indicate that anti-insulin antibody can be detected in subjects treated only with human insulin preparations (13, 14) and in type I diabetics prior to insulin therapy (15, 16) . In addition, recent studies in mice have shown that both helper and suppressor T cells are primed by insulins presumed to be "nonimmunogenic" (17, 18) and suggest that recognition of amino acid exchanges is not the only factor determining insulin immunity. Cellular responses to autologous insulins have not been examined in either inbred animals or human diabetic subjects. In this study, we show that the potential immunogenic epitopes on the insulin molecule are more numerous and complex than anticipated from results with inbred animals. In many cases these epitopes are present on both native and synthetic human insulin preparations. Differences in the amino acid sequence predict only a portion of the antigenic determinants present in insulin.
Methods
Patients. The subjects used in this study were identified by lymphocyte-proliferative responses to beef and pork insulins. Individuals with reproducible responses of >5,000 cpm were selected from 200 diabetic outpatients. This level of responsiveness per-INSULIN A CHAIN   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 HUMAN -G1y-I1e-Va1-G1u-G1n-Cys-Cys-Thr-Ser-I1e-Cys-Ser-Leu-Tyr-Gln-Leu-G1u-Asn-Tyr-Cys-Asn HUMAN -Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val -Glu-Ala-Leu-Tyr-Leu-Val -Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr scarce reagents. Reactivity ofthis magnitude is present in -20% of insulin treated diabetics (19 
Results
Patterns ofresponse to mammalian insulins. Assaying [3H]TdR uptake, we found -20% of diabetics develop strong T lymphocyte-proliferative responses (>5,000 cpm) to beef and pork insulin in vitro. To characterize the fine specificity of these responses, we compared the reactivity to several insulin concentrations using a battery of mammalian insulins. In general, three patterns of lymphocyte recognition can be detected, and these are summarized in Fig. 2 . Surprisingly, in some individuals the dose response curve to human insulin was identical to that obtained with animal insulins (Fig. 2 A) . Cells from other subjects ( Fig. 2 B and C) responded to animal insulins, but the responses were diminished or absent when human insulin was tested. Interestingly, lymphocytes that distinguish the A loop of beef insulin, where there are known amino acid differences from human insulin, were present in only a few subjects (4 of 25). This recognition was seen only with careful dose response curves (Fig.  2 C) . The four subjects in this group were the only patients found to respond to low doses of any insulin (10lMg), a concentration where the predominant molecular form is the monomer (2). In the following data, these general patterns of response are shown to be more complicated, however this arbitrary division serves as a guide for presentation of the complex data.
Responses with biosynthetic (recombinant DNA), semisynthetic (derived from pork insulin), and pancreatic (cadaver) human insulin preparations. Occasional individual variation that is not easily attributed to known structural changes is noted (e.g., C.W.). These differences suggest that these responses are heterogenous.
More than half of this group of subjects (four of seven) had type I diabetes. The data summarized in Fig. 4 show lymphocyte responses with preferential reactivity to animal insulins as compared to human insulin. However, at least 4 of 12 individuals show some reactivity with human insulin. This autoreactivity may represent cross-reactivity ofcells that have strong responses to heterologous insulins or it may be due to populations of cells that recognize epitopes similar to those recognized by the subjects in Fig. 3 . Previously, in studies that compared reactivities to beef and pork insulins only, responses such as in Fig. 4 nitude, is heterogenous; some require intact native conformation, others do not. Subject C.W. responds only to chain preparations that do not have blocked disulfide bridges, suggesting some conformational limitations to recognition of the isolated chains by his lymphocytes. All other subjects (Fig. 5 B, those with preferential reactivity to animal over human insulin, and Fig. 5 C, those with responses to low doses of beef insulin) respond to A and B chains preparations regardless of the presence of carboxymethyl groups used to block cysteines. In Fig. 5 C, only one of the individuals whose responses were preferential for the A-chain loop of intact beef insulin had a correspondingly greater reactivity to isolated A chain than with B chain (M.L.). Reactivity with B-chain residues, however, further confirms the interpretation that multiple determinants on both chains are recognized by these subjects. These results and those in Table I suggest that the epitopes recognized by human lymphocytes are more complex than some responses noted in inbred animals that appear to be directed at "single residues" (11, 23) . The weaker responses to isolated chains may be due to differences in the secondary structure between the chain and the native molecule as a result of disulfide bond recombination during chain isolation. The differences however, may also reflect disruption of epitopes that require the approximation of the A loop and the B-chain terminus. Also, recent studies of antigen processing in animal systems suggest that some T cells only recognize determinants after the antigen has been processed by the macrophage (24-26) . Thus, B-chain responses by cells from subjects whose predominant reactivity was directed at the A loop of intact beef insulin (Fig.   5 C) may suggest recognition of epitopes on the antigen-presenting cells in vitro that are not available on the intact molecule but arose through antigen processing at the injection site. Because processed insulin derivatives have not been identified in the circulation (27) (28, 29) . The degraded antigen, potentially in the form of peptides, is then reexpressed on the accessory cell surface in association with Ia antigens for recognition by T cells (26) . Studies with several defined proteins (ovalbumin, lysozyme, myoglobin, and cytochrome c) demonstrate that the epitopes recognized on the accessory cell surface may not be in the native molecule, but rather are a denatured or degraded form (24) (25) (26) 28) . The response to the "denatured" A-and B-chain preparations seen in most subjects (Fig. 5 B and C) may represent recognition of similar denatured determinants that arise from antigen processing ofinsulin. In addition, the preferential response to zinc insulin (human or animal) over sodium insulin by some subjects may indicate recognition of alterations in the molecule induced by zinc. This hypothesis is also supported by the observation that few subjects respond to low doses ofinsulin where the monomer is the predominant form. The responses at higher doses in most subjects are consistent with recognition of determinants found on dimers, hexamers, and other zinc-dependent aggregates. In that insulin is stored in islets complexed with zinc (2), it is interesting to speculate that the exposure to such determinants during islet cell destruction may be responsible for the anti-insulin antibodies found in association with the islet cell inflammation of type I diabetes. Because free zinc ions in sufficient concentration are mitogenic for T cells, an additional adjuvant effect ofzinc may also be postulated. In the preparations used, however, zinc is internalized in complexes of insulin. Furthermore, kinetics and ion concentration required for mitogenic responses to free zinc are different than the response to insulin (30 and unpublished observations). Antibody studies also support the concept that immunoreactive determinants on the molecules are present in zinc-dependent conformations (31, 32) . In studies with insulin antisera not only was zinc-free insulin shown to have marked decreased immunologic activity at concentrations where insulin was thought to be monomeric (31) , but it was also shown that addition of zinc restored immunologic activity (32) . Recognition of similar zinc-dependent immunogenic determinants by human lymphocytes is one potential explanation for the extensive cross-reactivity between human and animal insulins.
In addition to alterations of the insulin molecule to produce "neoantigenic" determinants, some of the reactivities with human insulin may be explained on the basis of cross-reactivities at high concentrations of antigen. This assay system does not permit us to distinguish cross-reactions from the combined responses of several clones. However, one subject with beef-preferential responses did not show reactivity to the highest concentration of human insulin (C.T., Table I ), indicating that crossreactivity of beef insulin-specific T cells will not always be seen with human insulin. This is further supported by the other subjects in Fig. 4 who also respond to animal insulins without reacting to human insulin. More important, autoimmunity to human insulin may stem from recognition of "self" epitopes by cells that escape normal immune regulation or tolerance mechanisms (18) . Whereas this possibility is not easily tested using species variants of insulin, some subjects were noted to require the serine at position A9 for optimal responses to low doses of beef insulin. This residue is also present in human insulin. The hydroxyl group of this senine has been shown to contribute to immunogenic determinants recognized by some mice (33), and may also be recognized by autoreactive T cells in humans. Similar epitopes may be involved in the complex cellular regulation recently shown in mice to control helper T cell generation for insulin (18) . These studies have recently been expanded to demonstrate that murine helper T cells can be generated with autologous insulin (Jensen, P. E., and J. A. Kapp, manuscript submitted for publication). This autoimmunity was detected when immunoregulatory circuits were removed. Likewise, our studies indicate the complexity of the human immune response to insulin may be enormous, and treatment with heterologous insulin may predispose to a more complex response by circumventing normal regulatory events. Similar studies carried out on individuals treated only with human insulin would help contrast the response with heterologous insulin and establish the role of both processed antigenic determinants and zinc-induced changes in immunogenicity. The detection of anti-insulin antibodies in subjects treated only with human insulin (13, 14) suggests that helper T cells recognizing human insulin can develop without the use of animal insulins.
Our preliminary attempts to use serological HLA detection to study the genetic contributions to these responses were disappointing. Three subjects with the strongest responses to beef insulin all had different DR types, and none had DR4 that was previously reported to be statistically associated with the beef response ( 12) . Although serologic typing may identify statistical associations with responsiveness in population studies, they are not predictive in individuals. In view of the multiple epitopes involved in the T cell responses, the racial mixture of our study population, and the complexity of human Ia antigens, we cannot justify the expense of serologic typing as a means to identify genetic contributions to the response. Rather, our current approach is to develop T cell lines reactive with individual epitopes. This will enable us to determine whether differences in the magnitude of responses are due to different frequencies of responding cells or to cross-reactivities of cells for different epitopes. Cell lines can be used to determine the role of antigen processing in the human T cell response to insulin. These lines can then be used to determine whether restriction elements for different epitopes are shared between individuals and may help identify important mechanisms that regulate the immune response to insulin in humans.
